- Home
- ZDGE vs SCYX Comparison
ZDGE vs SCYX Comparison
Compare ZDGE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- SCYX
- Stock Information
- Founded
- ZDGE 2008
- SCYX 1999
- Country
- ZDGE United States
- SCYX United States
- Employees
- ZDGE N/A
- SCYX N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- ZDGE Technology
- SCYX Health Care
- Exchange
- ZDGE Nasdaq
- SCYX Nasdaq
- Market Cap
- ZDGE 39.9M
- SCYX 34.9M
- IPO Year
- ZDGE N/A
- SCYX 2014
- Fundamental
- Price
- ZDGE $3.25
- SCYX $1.10
- Analyst Decision
- ZDGE
- SCYX
- Analyst Count
- ZDGE 0
- SCYX 0
- Target Price
- ZDGE N/A
- SCYX N/A
- AVG Volume (30 Days)
- ZDGE 41.8K
- SCYX 204.1K
- Earning Date
- ZDGE 10-28-2025
- SCYX 11-05-2025
- Dividend Yield
- ZDGE N/A
- SCYX N/A
- EPS Growth
- ZDGE N/A
- SCYX N/A
- EPS
- ZDGE N/A
- SCYX N/A
- Revenue
- ZDGE $29,511,000.00
- SCYX $3,257,000.00
- Revenue This Year
- ZDGE N/A
- SCYX $422.61
- Revenue Next Year
- ZDGE $2.95
- SCYX $240.56
- P/E Ratio
- ZDGE N/A
- SCYX N/A
- Revenue Growth
- ZDGE 1.27
- SCYX N/A
- 52 Week Low
- ZDGE $1.73
- SCYX $0.66
- 52 Week High
- ZDGE $4.89
- SCYX $1.66
- Technical
- Relative Strength Index (RSI)
- ZDGE 51.51
- SCYX 71.20
- Support Level
- ZDGE $2.91
- SCYX $0.81
- Resistance Level
- ZDGE $3.25
- SCYX $1.31
- Average True Range (ATR)
- ZDGE 0.17
- SCYX 0.07
- MACD
- ZDGE 0.05
- SCYX 0.03
- Stochastic Oscillator
- ZDGE 67.26
- SCYX 58.33
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.